Cancer Biomarkers Market Size & Share 2025 - 2034

Cancer Biomarkers Market Size

The global cancer biomarkers market size was estimated at USD 27.5 billion in 2024. The market is expected to grow from USD 30.7 billion in 2025 to USD 88.3 billion by 2034 at a CAGR of 12.4% from 2025 to 2034. Cancer biomarkers are biological molecules, which includes proteins, genes and other molecules. These molecules are found in the blood, tissues, or body fluids that indicates to detect the presence or prognosis of cancer. These biomarkers are used in early detection, diagnosis, monitoring treatment response, and designing personalized therapies to improve patient outcomes.

The global market is experiencing significant growth, driven by the increasing prevalence of cancer. For instance, according to the data from the World Health Organization (WHO), an estimated 20 million new cancer cases were reported in 2022, resulting in approximately 9.7 million deaths. It is estimated that 53.5 million people were living within five years of a cancer diagnosis.
 

Globally, about 1 in 5 individuals will develop cancer during their lifetime, with around 1 in 9 men and 1 in 12 women succumbing to the disease. These trends highlight the urgent need for advanced cancer biomarkers to accelerate early detection, accurate diagnosis, personalized treatment, and improved monitoring of cancer progression and therapy outcomes.
 

Additionally, innovations in personalized medicine for cancer biomarkers are  revolutionizing detection treatment and monitoring, which helps in escalating the market growth. Liquid biopsies have emerged as a non-invasive method for detecting tumor and other biomarkers in blood, which enables the early cancer diagnosis, real-time monitoring of treatment response. For example, according to the study published in the National Institute of Health (NIH) states that Guardant360 CDx has proven clinical validity in identifying patients with KRAS p.G12C–mutant non-small cell lung cancer (NSCLC). Its effectiveness improves when used alongside tissue-based tests, as recommended in its approved product label, ensuring comprehensive and accurate mutation detection.
 

Further, artificial intelligence in  healthcare (AI) and multi-omics approaches improve the diagnosis rate and treatment precision by combining genomic, proteomic, and metabolomic data. Moreover, technological advancements in diagnostic tools and increasing research and development activities are propelling the market growth.
 

 Cancer Biomarkers Market Trends

• Innovations in personalized medicine have transformed cancer care by utilizing biomarkers to deliver targeted treatments based on an individual's specific genetic, molecular, and clinical profile. These advancement has enable precise diagnostics, targeted therapies, and disease monitoring, helps in improving patient outcomes and minimizing the unnecessary treatments.
   
• Biomarkers have enhanced diagnostics accuracy by detecting genetic mutations, protein expressions, or epigenetic changes unique to an individual’s specific cancer. For instance, according to the study conducted in National Institute of Health states that, in breast cancers, targeted therapies such as trastuzumab and lapatinib has shown effectiveness in treatment. Thus, this significantly improves progression-free survival.
   
• Furthermore, biomarker-driven pharmacogenomics, which is estimated to reach USD 7.9 billion by 2032, tailors cancer treatments based on an individual’s genetic makeup. For example, KRAS mutation testing determines whether patients with colorectal cancer will respond to EGFR inhibitors, avoiding ineffective treatments.
   
• Additionally, biomarkers such as PD-L1 expression and tumor mutational burden (TMB) are being used to predict responses to immune checkpoint inhibitors, targeting immunotherapy approaches for cancer patients. Together, all these advancements not only enhance the precision and effectiveness of biomarkers  but also propel the growth of the market.
   

Cancer Biomarkers Market Analysis

Based on product, the market is segmented into instruments, consumables, and software. The global market was estimated at USD 24.7 billion in 2023. The instruments segment held revenue of USD 11.7 billion in 2024 and the segment is poised for significant growth at a CAGR of 12.3% during the forecast period.
 

• Instruments such a0073 PCR machines, next-generation sequencing (NGS) platforms, and mass spectrometers provides highest sensitivity and accuracy in detecting genetic mutations and biomarkers. These instruments allow multiplexing, allowing the fast analysis of multiple biomarkers in a single run, thereby saving time and reducing costs.
   
• For example, in September 2024, QIAGEN N.V. launched QIAcuityDx Digital PCR System, which provides highly precise, absolute quantitation of target DNA and RNA, supports applications with less invasive liquid biopsies. This PCR system also assists in monitoring cancer progression, complementing routine cancer diagnoses, which are performed by using next-generation sequencers (NGS).
   
• Additionally, technological advanced instruments increases biomarker testing speed, and also reduces turnaround times for diagnostics, which helps in supporting timely clinical decisions. For example, automated NGS systems provide comprehensive genomic profiling in hours rather than weeks.
   
• Furthermore, modern instruments which are integrated with AI and bioinformatics platforms, assisting the seamless analysis of complex datasets and the identification of actionable biomarker patterns for personalized treatment, thereby driving the market growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on cancer type, the cancer biomarkers market is bifurcated into breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, and other cancer types. The breast cancer segment accounted for a 28.6% market share in 2024 and is projected for significant growth to reach USD 25.9 billion by 2034.
 

• Cancer biomarkers helps in identifying breast cancer at an early stage. Common biomarkers such as CA 15-3 and CA 27-29 are specifically useful when they are combined with imaging techniques, such as mammography, to enhance diagnostic accuracy.
   
• In addition to this, the rising prevalence of the breast cancer is one of the key driver for the growth of the segment.
   
• For instance, as per the data from the American Cancer Society, in the U.S. it is projected that in 2025 around 316,950 women will be diagnosed from the invasive breast cancer, about 59,080 women will be diagnosed with ductal carcinoma in situ and approximately 42,170 women will die due to the breast cancer across the nation. Thus, as the diagnosis rate of breast cancer increases so does the need for effective diagnostic test in order to combat the disease.
   
• Further, biomarkers play a vital role in predicting disease outcomes. For instance, HER2 (Human Epidermal Growth Factor Receptor 2) overexpression is associated with aggressive tumors and higher recurrence risks. Patients with HER2-positive breast cancer are eligible for HER2-targeted therapies, such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine. These advantages are driving market growth.
   

Based on application, the cancer biomarkers market is bifurcated into drug discovery and development, diagnostics, personalized medicine, and other applications. The drug discovery and development segment accounted for a 40.2% market share in 2024.
 

• Drug discovery in cancer biomarkers focuses on identifying molecular targets that are linked to cancer's underlying mechanisms, which aims to develop therapies that are more precise and effective. Biomarkers helps to identify patients most likely to respond to specific treatments, thus personalizing the drug development process.
   
• The discovery process starts with identifying novel biomarkers associated with cancer. Researchers typically employ techniques which includes genomics, proteomics, and transcriptomics to recognize changes in the genetic or protein landscape of cancer cells.
   
• Furthermore, cancer biomarkers play a vital role in the development of targeted therapies, which are designed to specifically attack cancer cells with minimum effects on healthy cells. For instance, according to the National Cancer Institute of study states that the target mutated forms of the EGFR protein were approved for the use in people with non-small cell lung cancer (NSCLC). Thus, updated clinical trial showed that one of the newest EGFR-targeted drugs, osimertinib (Tagrisso), is more effective than earlier EGFR-targeted therapies in people whose NSCLC tumors have specific alterations in the EGFR gene.
   
• Thus, these targeted therapies can be small molecules or monoclonal antibodies that block the activity of specific proteins or signal pathways detected by biomarkers, thus propelling market growth.
   

Based on technology, the cancer biomarkers market is bifurcated into OMICS technologies and imaging technologies. Further, OMICS technologies are bifurcated into proteomics, genomics, and other omics technologies. The imaging technologies segment is segmented into ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography, mammography. The OMICS technologies segment accounted for a 58.2% market share in 2024.
 

• OMICS technologies, which includes genomics, proteomics, and metabolomics, facilitate a complete view of cancer biology, helps in identifying multiple biomarker types for more accurate detection, prognosis, and treatment strategies.  
   
• Further, genomic and proteomic profiling help identify cancer at its earliest stages by detecting molecular alterations before clinical symptoms appear, improving survival rates through early intervention.
   
• For instance, Galleri by GRAIL is a blood-based genomic test that detects many types of cancer which includes  all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases. The Galleri test screens for a unique "fingerprint" of cancer from DNA fragments shed from cancer cells. Thus, in a clinical study, it is stated that participants with a cancer diagnosis after a Cancer Signal Detected test result, the CSO was accurate 93.4% of the time.
   
• Additionally, by analyzing individual genetic makeup, OMICS technologies facilitate the development of targeted treatments, which ensures that therapies are more effective and minimizing adverse effects, further driving the market growth for cancer biomarkers.
   

Based on end use, the cancer biomarkers market is bifurcated into hospitals, diagnostic laboratories, biopharmaceutical companies, academic and research institutions, and other end users. The hospitals segment accounted for a 35.4% market share in 2024.
 

• Hospitals benefit from cancer biomarkers in the early detection and diagnosis of cancer. Biomarkers enable the identification of cancers at earlier stages, often before symptoms manifest.
   
• The growing cases of cancer and as well as the hospitalization and visiting rate of patients, fostering the need for effective treatment and diagnostic equipment in the hospital setting to delivery utmost care to the patients in this setting, thereby fostering the growth of the segment.
   
• Cancer biomarkers play a vital role in personalizing treatment strategies. By examining the molecular characteristics of a patient’s tumor, hospitals can select specific targeted therapies that are more likely to be effective for that individual patient.
   
• Additionally, the growing demand for the non-invasive treatment option for the cancer treatment such as immunotherapy and personalized medicines, has stimulated the adoption of these therapies in the hospitals. Since these advance therapies necessitates highly skilled personnel which is readily available in the hospital setting, thereby the segment remains in the forefront in the rapidly evolving market of cancer biomarkers, further boosting the market growth.
   

The North America cancer biomarkers market is accounted for USD 11.2 billion revenues in 2024 forecasted to reach USD 35.2 billion by 2034. The U.S. dominated the North America market with the largest revenue of USD 9.2 billion in 2023.
 

• The increasing prevalence of the cancer in the U.S. in the key driver for the growth of the market in the U.S.
   
• For instance, as per the data from the American Cancer Society in 2025, around 2,041,910 new cases of cancer are to be diagnosed and 618,120 cases of cancer related deaths is projected to occur in the U.S.
   
• Thus, this rising burden of the cancer is propelling the market in the U.S. as many pharmaceutical and biotechnology companies, hospitals and research institutes are undertaking various research to develop advanced diagnostic solutions and therapies to the combat the disease in the country.
   

Europe: The cancer biomarkers market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The UK government is heavily investing in the cancer research, treatment advancement, and in early detection programs.
   
• For instance, in 2022, as per the data from University of Oxford, the Cancer Research UK had invested around EUR 11 million in the cancer science research in Oxford.
   
• Thus, these investment is anticipated to stimulate groundbreaking discovery in the research pertaining to cancer and enhance early diagnosis, accelerating the market growth in the country.
   

Asia Pacific: Japan cancer biomarkers market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The country as one of speediest aging population which needs frequent health monitoring. For instance, according to the World Health Organization, in 2021, Japan's elderly population, aged 65 and above, comprised 29.1% of the total population.
   
• This demographic shift has led to a rise in age-related diseases, with cancer as the leading cause of death, accounting for 27% of all fatalities in Japan, as reported by the National Cancer Center Japan in 2022. Thus, this rising disease burden has surged the demand for effective targeted therapies, escalating the growth of the companion diagnostic in Japan.
   
• Thus, as the population ages in the country so does the chances of cancer, thereby fostering the market growth in the country.
   

Middle East and Africa: The cancer biomarkers market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia has experienced rise in early cancer detection due to growing awareness and improved screening programs. Thus, this trend encourages earlier treatment and heightens the demand for cancer biomarkers.
   
• Further, Saudi Arabia’s advance healthcare infrastructure and rising investment in advanced healthcare technologies create opening for the development and adoption of advanced cancer biomarkers tailored to the country’s patient specific needs.
   

Cancer Biomarkers Market Share

The top 4 players of the market account for approximately 45% of the market share which includes companies such as Abbott Laboratories, F. Hoffmann-La Roche, Illumina, Thermo Fisher Scientific, among others. With every firm introducing new products such as instruments, kits, assay and using advanced technologies, modernization is extremely important.
 

Moreover, strategic partnerships with research institutes, and government agencies play a primary role in advancing the development of new products and getting the necessary permits. The enhancement of public awareness about cancer and its health impact through the social media platform, will encourage more individuals to seek the treatment, assisting market players to strengthen their position in this growing sector.
 

 Cancer Biomarkers Market Companies

Some of the eminent market participants operating in the cancer biomarkers industry include:

• Abbott Laboratories
• Agilent Technologies
• Bio-Rad Laboratories
• Becton, Dickinson and Company
• BioGenex
• Centogene
• F. Hoffmann-La Roche
• Hologic
• INOVIQ
• Illumina
• Merck & Co.
• QIAGEN
• Sino Biological
• Sysmex Corporation
• Thermo Fisher Scientific
   
• Agilent Technologies has robust geographical presence which enables it to enhance its market reach. Agilent Technologies operates in more than 110 countries thus comprising of a strong distribution network.
   
• F. Hoffmann-La Roche Ltd has strong global workforce of approximately 100,000+ employees, which enables the company to drive innovation, and deliver high-quality solutions.
   
• Merck & Co has a strong financial position; the company had reported a total revenue of USD 60,115 million for the financial year 2023.
   

Cancer Biomarkers Industry News:

• In August 2024, Illumina, Inc. received FDA approval for its in vitro diagnostic test, TruSight Oncology Comprehensive, which analyzes over 500 genes in a patient's solid tumor. This test aimed to enhance the identification of oncology biomarkers, marking a major advancement in personalized cancer treatment by enabling more precise and targeted therapies.
   
• In April 2021, Roche launched the Elecsys Anti-p53 immunoassay, a cancer biomarker test designed to detect anti-p53 antibodies in serum and plasma. This diagnostic tool aided physicians in diagnosing various cancers, including throat, bowel, and breast cancer, when used in conjunction with other diagnostic methods. Thus, this launch strengthened the Roche product portfolio in cancer and enhanced its market position in cancer biomarkers.
   

The cancer biomarkers market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Consumables
• Software

Market, By Cancer Type

• Breast cancer
• Prostate cancer
• Colorectal cancer
• Cervical cancer
• Liver cancer
• Lung cancer
• Other cancer types

Market, By Application

• Drug discovery and development
• Diagnostics
• Personalized medicine
• Other applications

Market, By Technology

• OMICS technologies
  • Proteomics
  • Genomics
  • Other OMICS technologies
• Imaging technologies
  • Ultrasound
  • Computed tomography
  • Magnetic resonance imaging
  • Positron emission tomography
  • Mammography

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Biopharmaceutical companies
• Academic and research institutions
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE